CSR Analysis Alentis Therapeutics
alentis.chDevelopment of innovative treatments targeting Claudin-1 for cancer and organ fibrosis. The company develops antibodies and antibody-drug conjugates to treat Claudin-1-positive tumors and multi-organ fibrotic diseases.
B
CSR Analysis score
The organization is among the top 20% of most committed organizations, excluding the top 5%, among comparable organizations.
EmpCo Directive — September 27, 2026
Greenwashing: does Alentis Therapeutics's communication contain risky green claims?
We analyzed the websites of over 250,000 companies, including Alentis Therapeutics's, to extract CSR initiatives and communications containing risky environmental claims.
Greenwashing risk score + your position within your sector
Sector data Industrie pharmaceutique et biotechnologies
8,585CSR initiatives analyzed in sector Industrie pharmaceutique et biotechnologies
2,292Companies in sector Industrie pharmaceutique et biotechnologies
1,237SMEs (10 to 250 employees) in sector Industrie pharmaceutique et biotechnologies
+250,000
Total organizations analyzedDiscover our sector reports
Detailed analysis by theme
Analysis by axis
Discover the complete analysis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
How are these scores calculated?
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: October 2026
They trust us
